UNITED STATES
                                  -------------
                       SECURITIES AND EXCHANGE COMMISSION
                       ----------------------------------
                             Washington, D.C.  20549
                             -----------------------

                                    FORM 10-Q
                                    ---------

                  Quarterly Report Under Section 13 or 15(d) of
                  ---------------------------------------------
                       The Securities Exchange Act of 1934
                       -----------------------------------



For  quarter  ended:  September  30, 1999           Commission File No. 1-12575
                                                                       --------


                           UTAH MEDICAL PRODUCTS, INC.
                           ---------------------------
             (Exact name of Registrant as specified in its charter)


            UTAH                                             87-0342734
     -----------------                                   ---------------
     (State  or  other  jurisdiction  of               (I.R.S.  Employer
     incorporation  or  organization)                 Identification  No.)


                               7043 South 300 West
                               Midvale, Utah  84047
                        --------------------------------
                     Address of principal executive offices


Registrant's  telephone  number:     (801)  566-1200
                                     ---------------


     Indicate  by  check  mark  whether the registrant (1) has filed all reports
required  to  be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or  for  such shorter period that the
registrant  was required to file such reports) and; (2) has been subject to such
filing  requirements  for  the  past  90  days.      Yes  X     No
                                                          -

  The  number  of  shares  outstanding  of  the  registrant's common stock as of
November  11,  1999:  6,453,000
                      ---------
<PAGE>

                           UTAH MEDICAL PRODUCTS, INC.
                           ---------------------------

                               INDEX TO FORM 10-Q
                               ------------------

PART  I  -  FINANCIAL  INFORMATION                                          PAGE
                                                                            ----


  Item  1.  Financial  Statements

     Consolidated  Condensed  Balance  Sheets  as  of
     September  30,  1999  and  December  31,  1998                           1

     Consolidated  Condensed  Statements  of  Income  for  the
     three  and  nine  months  ended  September  30, 1999 and
     September 30, 1998                                                       2

     Consolidated  Condensed  Statements  of  Cash  Flows  for  the
     nine months ended September 30, 1999 and September 30, 1998              3

     Notes  to  Financial  Statements                                         4


  Item  2.  Management's  Discussion  and  Analysis  of
             Financial  Condition  and  Results  of  Operations               6

PART  II  -  OTHER  INFORMATION

  Item  6.  Exhibits  and  Reports  on  Form 8-K                             11


SIGNATURES                                                                   11
<PAGE>

                        PART I  -  FINANCIAL INFORMATION
ITEM  1.  FINANCIAL  STATEMENTS

                 UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
                  --------------------------------------------
                   CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
                   -------------------------------------------
                    SEPTEMBER 30, 1999 AND DECEMBER 31, 1998
                    ----------------------------------------
                           (in thousands - unaudited)
<TABLE>
<CAPTION>



<S>                                                        <C>                   <C>
ASSETS. . . . . . . . . . . . . . . . . . . . . . . . . .  SEPTEMBER 30, 1999    DECEMBER 31, 1998
---------------------------------------------------------  --------------------  -------------------

CURRENT ASSETS:
Cash. . . . . . . . . . . . . . . . . . . . . . . . . . .  $               569   $            1,367
Accounts receivable - net . . . . . . . . . . . . . . . .                4,441                4,531
Inventories . . . . . . . . . . . . . . . . . . . . . . .                3,344                4,048
Other current assets. . . . . . . . . . . . . . . . . . .                  641                  597
                                                                        -------             -------
Total current assets. . . . . . . . . . . . . . . . . . .                8,995               10,543

PROPERTY AND EQUIPMENT - NET. . . . . . . . . . . . . . .               11,494               12,489

INTANGIBLE ASSETS - NET . . . . . . . . . . . . . . . . .                8,418                8,936
                                                           --------------------  -------------------

TOTAL . . . . . . . . . . . . . . . . . . . . . . . . . .  $            28,907   $           31,968
                                                           ====================  ===================

LIABILITIES AND STOCKHOLDERS' EQUITY
---------------------------------------------------------

CURRENT LIABILITIES:
Accounts payable. . . . . . . . . . . . . . . . . . . . .  $               560   $              525
Accrued expenses. . . . . . . . . . . . . . . . . . . . .                1,810                1,886
Deferred revenue. . . . . . . . . . . . . . . . . . . . .                    0                    2
                                                           --------------------  -------------------

Total current liabilities . . . . . . . . . . . . . . . .                2,370                2,413

NOTES PAYABLE . . . . . . . . . . . . . . . . . . . . . .                8,538                3,098

DEFERRED INCOME TAXES . . . . . . . . . . . . . . . . . .                  356                  440
                                                           --------------------  -------------------

Total liabilities . . . . . . . . . . . . . . . . . . . .               11,264                5,951
                                                           --------------------  -------------------

STOCKHOLDERS' EQUITY:
Preferred stock - $.01 par value; authorized - 5,000
  shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000
  shares; issued - September 30, 1999, 6,453 shares
  December 31, 1998, 8,046 shares . . . . . . . . . . . .                   65                   80
Cumulative foreign currency translation adjustment. . . .                 (973)                (509)
Retained earnings . . . . . . . . . . . . . . . . . . . .               18,551               26,446
Total stockholders' equity. . . . . . . . . . . . . . . .               17,643               26,017
                                                           --------------------  -------------------

TOTAL . . . . . . . . . . . . . . . . . . . . . . . . . .  $            28,907   $           31,968
                                                           ====================  ===================
see notes to consolidated condensed financial statements
</TABLE>


                                         -1-


                  UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
                  --------------------------------------------
             CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS FOR THE
             -------------------------------------------------------
      THREE AND NINE MONTHS ENDED SEPTEMBER 30, 1999 AND SEPTEMBER 30, 1998
      ---------------------------------------------------------------------
                           (in thousands - unaudited)
<TABLE>
<CAPTION>

                                                      THREE MONTHS ENDED     NINE MONTHS ENDED
                                                          SEPTEMBER 30,        SEPTEMBER 30,
                                                          -------------       -------------
                                                           1999    1998       1999     1998
                                                          ------  ------     -------  -------
<S>                                                       <C>     <C>        <C>      <C>
NET SALES. . . . . . . . . . . . . . . . . . . . . . . .  $7,568  $7,150     $21,905  $20,311

COST OF SALES. . . . . . . . . . . . . . . . . . . . . .   3,464   3,430      10,244    9,983
                                                          ------  ------     -------  -------

GROSS MARGIN . . . . . . . . . . . . . . . . . . . . . .   4,104   3,720      11,661   10,328
                                                          ------  ------     -------  -------

EXPENSES:

Selling, general and administrative. . . . . . . . . . .   1,658   1,707       5,092    4,918
Research & development . . . . . . . . . . . . . . . . .     194     231         556      697
                                                          ------  ------     -------  -------

Total. . . . . . . . . . . . . . . . . . . . . . . . . .   1,852   1,938       5,648    5,615
                                                          ------  ------     -------  -------

INCOME FROM OPERATIONS . . . . . . . . . . . . . . . . .   2,252   1,782       6,013    4,713

OTHER INCOME . . . . . . . . . . . . . . . . . . . . . .      71     209         293      836
                                                          ------  ------     -------  -------

INCOME BEFORE INCOME TAX EXPENSE . . . . . . . . . . . .   2,323   1,991       6,305    5,549

INCOME TAX EXPENSE . . . . . . . . . . . . . . . . . . .     836     701       2,270    1,973
                                                          ------  ------     -------  -------

NET INCOME . . . . . . . . . . . . . . . . . . . . . . .  $1,486  $1,290     $ 4,035  $ 3,576
                                                          ======  ======     =======  =======

BASIC EARNINGS PER SHARE . . . . . . . . . . . . . . . .  $ 0.22  $ 0.16     $  0.54  $  0.43
                                                          ======  ======     =======  =======

DILUTED EARNINGS PER SHARE . . . . . . . . . . . . . . .  $ 0.22  $ 0.16     $  0.54  $  0.43
                                                          ======  ======     =======  =======

SHARES OUTSTANDING - BASIC . . . . . . . . . . . . . . .   6,727   8,297       7,435    8,305
                                                          ======  ======     =======  =======

SHARES OUTSTANDING - DILUTED . . . . . . . . . . . . . .   6,774   8,317       7,448    8,320
                                                          ======  ======     =======  =======

see notes to consolidated condensed financial statements
</TABLE>

                                            -2-



                  UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
                  --------------------------------------------
                 CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                 -----------------------------------------------
       FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1999 AND SEPTEMBER 30, 1998
       -------------------------------------------------------------------
                           (in thousands - unaudited)
<TABLE>
<CAPTION>

                                                                 SEPTEMBER 30,
                                                                -------------
                                                                   1999      1998
                                                               ---------  --------
<S>                                                            <C>        <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income. . . . . . . . . . . . . . . . . . . . . . . . . .  $  4,035   $ 3,576
                                                               ---------  --------
Adjustments to reconcile net income to net
    cash provided by operating activities:
    Depreciation and amortization . . . . . . . . . . . . . .     1,615     1,518
    Provision for (recovery of) losses on accounts receivable       (20)       26
    (Gain)/Loss on disposal of assets . . . . . . . . . . . .        (1)      439
    Deferred income taxes . . . . . . . . . . . . . . . . . .       (94)      (24)
    Tax benefit attributable to exercise and disposition
      of incentive stock options and stock purchase rights. .         1         0
Changes in operating assets and liabilities:
    Accounts receivable - trade . . . . . . . . . . . . . . .      (312)      256
    Accrued interest and other receivables. . . . . . . . . .       370      (727)
    Inventories . . . . . . . . . . . . . . . . . . . . . . .       754     1,717
    Prepaid expenses. . . . . . . . . . . . . . . . . . . . .       (34)       (3)
    Accounts payable. . . . . . . . . . . . . . . . . . . . .        35       (94)
    Accrued expenses. . . . . . . . . . . . . . . . . . . . .       (88)      163
    Deferred revenue. . . . . . . . . . . . . . . . . . . . .        (2)      (64)
                                                               ---------  --------
Total adjustments . . . . . . . . . . . . . . . . . . . . . .     2,224     3,207
                                                               ---------  --------
Net cash provided by operating activities . . . . . . . . . .     6,259     6,783
                                                               ---------  --------

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
    Property and equipment. . . . . . . . . . . . . . . . . .      (535)     (337)
    Intangible assets . . . . . . . . . . . . . . . . . . . .        (2)     (289)
Proceeds from sale of property and equipment. . . . . . . . .         1        11
Net cash paid in acquisition. . . . . . . . . . . . . . . . .              (4,188)
                                                               ---------  --------
Net cash used in investing activities . . . . . . . . . . . .      (536)   (4,803)
                                                               ---------  --------

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock. . . . . . . . . . . .        98        58
Common stock purchased and retired. . . . . . . . . . . . . .   (12,058)     (448)
Increase in note payable. . . . . . . . . . . . . . . . . . .     5,444        49
                                                               ---------  --------
Net cash used in financing activities . . . . . . . . . . . .    (6,516)     (341)
                                                               ---------  --------

Effect of exchange rate changes on cash . . . . . . . . . . .        (4)       42

NET INCREASE (DECREASE) IN CASH . . . . . . . . . . . . . . .      (798)    1,681

CASH AT BEGINNING OF PERIOD . . . . . . . . . . . . . . . . .     1,367       951
                                                               ---------  --------

CASH AT END OF PERIOD . . . . . . . . . . . . . . . . . . . .  $    569   $ 2,632
                                                               =========  ========

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
  Cash paid during the period for income taxes. . . . . . . .  $  2,247   $ 1,606
  Interest. . . . . . . . . . . . . . . . . . . . . . . . . .  $    167   $   243
see notes to consolidated condensed financial statements
</TABLE>
<PAGE>
                                       -3-


                           UTAH MEDICAL PRODUCTS, INC.
                           ---------------------------
              NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
              ----------------------------------------------------
                                   (unaudited)

(1)     The  unaudited  financial statements presented herein have been prepared
in  accordance  with the instructions to form 10-Q and do not include all of the
information  and  note  disclosures  required  by  generally accepted accounting
principles.  These  statements  should be read in conjunction with the financial
statements  and  notes included in the Utah Medical Products, Inc. ("UM" or "the
Company")  annual  report  on  form  10-K  for the year ended December 31, 1998.
Although  the  accompanying  financial  statements  have  not  been  examined by
independent  accountants  in  accordance  with  generally  accepted  auditing
standards,  in  the opinion of management, such financial statements include all
adjustments  (consisting  only  of  normal  recurring  adjustments) necessary to
summarize  fairly  the  Company's  financial position and results of operations.

(2)     Inventories  at  September 30, 1999 and December 31, 1998 (in thousands)
consisted  of  the  following:

                                        September 30,           December 31,
                                             1999                  1998
                                        ---------               ---------
          Finished  goods                $   899                 $  1,041
          Work-in-process                    868                      771
          Raw  materials                   1,577                    2,236
                                          ------                    -----
          Total                           $3,344                   $4,048
                                          ======                   ======


(3)     In  June 1998, the Financial Accounting Standards Board issued Statement
of  Financial  Accounting  Standards  (SFAS) No. 133, "Accounting for Derivative
Instruments  and Hedging Activities."  This statement establishes accounting and
reporting  standards  for derivative instruments and requires recognition of all
derivatives  as assets or liabilities in the statement of financial position and
measurement  of those instruments at fair value.  The statement is effective for
fiscal  years  beginning  after June 15, 2000.  UM believes that the adoption of
SFAS  133  will  not  have  a material effect on the financial statements of the
Company.

(4)     On  August  9,  1999,  UM  reported  final  results  of its tender offer
announced  May  26, 1999.  A total of 1,273,322 shares were validly tendered and
not  withdrawn, and 1,153,945 of those shares were purchased by the Company at a
price  of  $8.00  per share.  The shares purchased represent about 15% of shares
outstanding  prior  to  the  tender  offer.

(5)     The  Company has adopted SFAS No. 130, "Reporting Comprehensive Income."
This  standard  requires  companies  to  disclose  certain changes in equity not
represented  in  net income such as foreign currency translation adjustments and
unrealized  gains/losses  on  available-for-sale  securities.  These  items  are
components  of  other  comprehensive  income  which,  when  added to net income,
represent  total  comprehensive  income.  The Company translates the currency of
its  Ireland  subsidiary which comprises the only element of other comprehensive
income.  Total  comprehensive  income  for  the  quarter  and nine months ending
September  30,  1999  was,  respectively  (in  thousands)  $1,684  and  $3,585.

(6)     Forward-Looking  Information
     This  report  contains  certain  forward-looking statements and information
relating  to  the Company that are based on the beliefs of management as well as
assumptions  made  by, and information currently available to, management.  When
used  in this document, the words "anticipate," "believe," "should,"  "project,"
"estimate,"  "expect,"  "intend"  and similar expressions, as they relate to the
Company  or its management, are intended to identify forward-looking statements.
Such statements reflect the current view of the Company respecting future events
and  are subject to certain risks, uncertainties, and assumptions, including the
risks and uncertainties noted throughout the document.  Although the Company has
attempted  to  identify important factors that could cause the actual results to
differ  materially,  there may be other factors that cause the forward statement
not  to  come  true  as anticipated, believed, projected, expected, or intended.
Should  one  or  more  of  these  risks  or uncertainties materialize, or should
underlying  assumptions  prove  incorrect,  actual results may differ materially
from  those  described  herein  as  anticipated, believed, projected, estimated,
expected,  or  intended.
     General  risk  factors  that  may impact the Company's revenues include the
market  acceptance  of  competitive  products,  obsolescence  caused  by  new
technologies,  the  possible  introduction  by  competitors of new products that
claim  to  have  many  of  the  advantages of UM's products at lower prices, the
timing and market acceptance of UM's own new product introductions, UM's ability
to efficiently manufacture its products, including the reliability of suppliers,
year  2000  problems, success in gaining access to important global distribution
channels,  marketing  success of UM's distribution and sales partners, budgetary
constraints,  the  timing of regulatory approvals for newly introduced products,
third party reimbursement, and access to U.S. hospital customers, as that access
is  increasingly  constrained  by  group  purchasing  decisions.
     Risk  factors,  in addition to the risks outlined in the previous paragraph
that  may  impact  the  Company's assets and liabilities, as well as cash flows,
include  risks  inherent to companies manufacturing products used in health care
including  claims  resulting  from the improper use of devices and other product
liability claims, defense of the Company's intellectual property, productive use
of  assets  in  generating  revenues,  management  of  working capital including
inventory  levels  required  to meet delivery commitments at a minimum cost, and
timely  collection  of  accounts  receivable.
     Additional  risk  factors  that may affect non-operating income include the
continuing viability of the Company's technology license agreements, actual cash
and investment balances, asset dispositions, and acquisition activities that may
require  external  funding.


<PAGE>
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF  OPERATIONS

Analysis  of  Results  of  Operations
          Because  of  the  relatively short span of time, results for any given
three  month  period in comparison with a previous three month period may not be
indicative  of  comparative results for the year as a whole.  Dollar amounts are
in  thousands,  except  per-share  amounts  and  where  noted.

     a)     Overview
          All  key  measures  of  UM's financial performance were positive in 3Q
1999  compared  to  3Q 1998.  Sales in 3Q 1999 increased 6% from 3Q 1998.  Gross
profit  margins  set  a  new  UM record at 54.2% of sales.  Further leverage was
achieved  in operating margins as operating expenses declined 4% in 3Q 1999 from
3Q 1998.  Earnings per share (EPS) increased 41% in 3Q 1999 compared to 3Q 1998.
Over the same period, EPS grew faster than operating profits, because there were
1,543,000  fewer  diluted  shares outstanding in 3Q 1999.  Results for the first
nine  months  (9M)  of  1999 compared to 9M 1998 in a similar way.  Other income
declined  $543  in  9M  1999  compared to 9M 1998, mainly due to UM's receipt of
payments  for use of its technology in 1Q and 3Q 1998, neither of which recurred
in  9M  1999.  Sales from UM's  1998 acquisition of the neonatal product line of
Gesco  International  Inc.  and  Bard Access Systems, Inc. were included in UM's
results for the first time in third quarter 1998.  With a strong cash flow, UM's
long  term  debt  balance  increased  by  just  $5.4 million in 9M 1999, despite
repurchase  of 1,606,000 shares of its stock for $12.1 million during that time.

     b)     Revenues
          Following  the  acquisition of the Gesco neonatal product line from CR
Bard  in  third  quarter  1998,  UM  divides  its  sales  into four product-line
categories:  1)  obstetrics,  comprising labor and delivery management tools for
monitoring fetal and maternal well-being, for improving clinician safety and for
ease  in  performing  delivery procedures; 2) gynecology/electrosurgery/urology,
consisting  of  tools  for  gynecological  office/clinician practices, including
LETZ,  endometrial  sampling,  diagnostic laparoscopy, and other MIS procedures;
specialty excision and incision tools; conservative urinary incontinence therapy
devices; and urology tools; 3) neonatal, comprising devices for gaining vascular
access,  administering  vital fluids, maintaining a neutral thermal environment,
and  other  specialized tools used in the care of critically-ill infants; and 4)
blood  pressure  monitoring/accessories/other,  consisting of transducer systems
for  invasively  monitoring  blood  pressure  on  a continuous basis, along with
products  sold  on  an  OEM  basis  to  other  companies.  UM's  primary revenue
contributors  generally  enjoy  a  dominant  market  share  and  typically  have
important  product  features  protected  by  patents.
          Sales  in  the  obstetrics  product  category  were $3,614 in 3Q 1999,
compared  to  $3,880  in  3Q  1998.  First  nine months 1999 sales of obstetrics
products  were  $10,442  compared  to  $10,911  in 9M 1998.  The decline was due
mainly  to  weakness  in vacuum-assisted delivery system (VADS) sales.  In April
1999, UM introduced a mushroom shaped soft rubber cup, the Secure Cup , designed
to  provide  a  balance between holding power and safety.  In September 1999, UM
announced  that  Novation LLC, the supply company of VHA Inc. and the University
HealthSystem  Consortium,  has  awarded a sole source supply agreement to UM for
the  Intran  Plus  family  of  products.  Members  of  Novation  deliver  about
one-third  of  births in the U.S.  UM believes the new partnership of its direct
sales  resources  with  the  excellent  Novation marketing team will help create
opportunities  for UM to engage in effective communications with clinicians that
it  otherwise might not enjoy.   Novation has a history of considering the needs
of its Members' clinicians, and establishing supply agreements based on quality,
reliability  and  other  clinical  considerations  in  addition  to  financial
considerations.  As a result of the agreement, UM expects to increase unit sales
of  its  IUPCs  to  Novation  Members.
          Gynecology/electrosurgery/urology  product sales were up 4% in 3Q 1999
over 3Q 1998, and represented 15% of total revenues. Sales in this category were
$1,111 in 3Q 1999, compared to $1,072 in 3Q 1998.  Comparing 9M 1999 to 9M 1998,
gynecology/electrosurgery/urology  sales  were  $3,229 and $3,154, respectively.
Gains  in  sales  of  Liberty  ,  Pathfinder , Epitome  and loop electrodes were
offset  somewhat  by  lower  sales of OEM vacuum erection pumps.  Marketing this
group  of  products  requires  multiple sales call points and extensive clinical
training  and  familiarization time with users, among other economic challenges.
          In  late July 1998, a significant UM initiative was the acquisition of
the  neonatal product line of Gesco International.  Because of the acceptance of
the  renowned  Gesco  products  and  their  growth  potential,  UM now separates
neonatal  product sales and BPM product sales.  Compared to 3Q 1998 and 9M 1998,
UM's 3Q 1999 and 9M 1999 neonatal product sales grew 59% and 173%, respectively.
Neonatal  product sales were $1,009 in 3Q 1999, compared to $636 in 3Q 1998, and
represented  13%  of  total revenues in 3Q 1999.  Sales in this product category
were  $2,774  in 9M 1999, compared to $1,015 in 9M 1998.  UM's growth throughout
1999  has  been  primarily  driven  by  the  neonatal  product  line.
          BPM and accessories sales represented 24% of 3Q 1999 sales, increasing
2%  from  the  same quarter of the prior year.  Sales of BPM products in 3Q 1999
were  $1,834, compared to $1,563 in 3Q 1998, and were $5,460 in 9M 1999 compared
to  $5,231  in  9M  1998.  In this category, UM depends heavily on the marketing
efforts  of  other  medical device companies (the OEM channel), both in the U.S.
and  overseas.  Global  OEM  sales  increased  5%  in  3Q  1999 from 3Q 1998 and
decreased  3%  in 9M 1999 compared to the same period of 1998.  Global OEM sales
in  both 3Q 1999 and 1998 were 14% of total sales, and were 14% of 9M 1999 sales
compared  to 16% of 9M 1998 sales.  UM projects demand for its BPM products will
remain  stable  for  the  foreseeable  future.
          Foreign  sales were $1,386 and $3,958 in 3Q and 9M 1999, respectively,
compared  to  $1,084  and $3,561 in 3Q and 9M 1998, respectively.  Foreign sales
represented  18%  of global sales in 3Q 1999 compared to 15% in the same quarter
of  1998.  The  increase  is due to higher direct foreign sales, across all four
product  categories.  Ob/Gyn and neonatal foreign sales increased 20% to $332 in
3Q  1999 compared to $276 in 3Q 1998. Ob/Gyn and neonatal product sales were 24%
of 3Q 1999 foreign sales, compared to 25% in 3Q 1998.  UM expects to continue to
increase  foreign  sales  as  it  recruits effective international distributors.

     c)     Gross  Profit
          The gross profit margin (GPM), the surplus remaining after subtracting
costs of manufacturing products from net revenues, in 3Q and 9M 1999 was 54% and
53%,  respectively,  compared to 52% and 51% in 3Q and 9M of 1998, respectively.
Manufacturing  operations  in all locations (Ireland, Oregon and Utah) continued
to  perform  well  in 3Q 1999.  UM management believes that achieving an average
GPM  above  50%  is  necessary  to  successfully cover the significant sales and
marketing, research and development, and administrative expenses associated with
a growth company in a highly complex and competitive marketplace.  The improving
average GPM trend is explained by observing that UM has become less dependent on
lower  margin  OEM  sales,  has  developed its own direct sales force to replace
lower  margin  sales  through distributors, and has increased revenues without a
comparable  increase  in  manufacturing  overhead.

     d)     Income  from  Operations
          Operating  profit, or income from operations, is the surplus remaining
after subtracting operating expenses from gross profits.  Operating expenses are
subdivided  into  sales, general and administrative expenses (SG&A) and research
and development expenses (R&D).  UM further divides SG&A into the two categories
of  sales  and  marketing expenses (S&M) and general and administrative expenses
(G&A).  Operating profits increased 26% and 28% in 3Q and 9M 1999, respectively,
each  more  than three times the growth rate in sales for both periods, and more
than  two  times  the growth rate in gross profits over the same periods.  Total
operating  expenses  were  24.4%  and  25.8%  of  sales  in  3Q  and  9M  1999,
respectively,  compared  to  27.1%  and  27.7%  of  sales  in  3Q  and  9M 1998,
respectively.
          SG&A  expenses  in 3Q 1999 improved to 21.9% of revenues from 23.9% of
3Q  1998  revenues,  and  were 23.2% of 9M 1999 revenues compared to 24.2% of 9M
1998  revenue.  The  G&A expenses portion increased to $736 in 3Q 1999 from $712
in  3Q 1998, and to $2,233 in 9M 1999 from $2,011 in 9M 1998, due essentially to
increased  expenses  from  goodwill  amortization  (GWA)  associated with recent
acquisitions.  GWA  was $427 in 9M 1999, compared to $290 in 9M 1998.  Since the
result  of  the acquisitions were marketable new products for UM, these expenses
can  be  regarded  as  a surrogate to R&D expenses although they are captured in
G&A.
          S&M  expenses  are  the  costs  of  promoting,  selling  and providing
customer  support  of UM's products.  Although sales and GPMs improve when sales
are  made through directly employed sales representatives in lieu of independent
distributors  or  OEM  customers,  S&M operating expenses increase as an offset.
Global  sales in 3Q and 9M 1999 increased 6% and 8%, respectively, from the same
periods  of  1998,  while  S&M  expenses  decreased 7% and 2% in 3Q and 9M 1999,
respectively, improving the productivity of S&M resources.  The majority of UM's
S&M  expenses  pertain to the U.S. "direct sales" portion of its business.  U.S.
direct  sales  increased 8% in 9M 1999 from the same period of 1998.  Recruiting
and  training  sales  professionals  who  can  effectively  implement  UM's
solutions-oriented  approach  is  a  key  to  UM's  success.
          R&D  expenses  in  3Q  and  9M  1999  were  2.6%  and  2.5%  of sales,
respectively,  compared  to  3.2%  and  3.4%  of  sales  in  3Q  and  9M  1998,
respectively.  Internal  development  of UM's fetal tissue pH project, which had
consumed  over  half  of  R&D  expenses  since  the end of 1997, was scaled back
considerably  in  second  and  third  quarter  1999.  UM  has  not achieved some
important milestones relating to the calibration of the device in living tissue.
Other  key  R&D  projects  receiving  funding  include development of the Fowler
Endocurette, enhancements to both CMI VADS and Gesco neonatal product lines, and
continuing  improvements  to  Liberty,  Deltran Plus and Cordguard.  A number of
important  improvements  in  materials and configuration of components have been
achieved  in  1999 which will reduce manufacturing costs and/or increase product
quality.   At  UM,  R&D  resources  are  kept  involved  in  the  support  of
manufacturing  processes,  as UM finds it makes long term sense to keep its most
technical  people  involved  with  products  throughout  their  life  cycles.

     e)     Non-operating  (Other)  income.
          Non-operating  income includes primarily royalties from licensing UM's
technology  to  other  companies,  but  also  interest  and  capital  gains from
investing  the  Company's  cash offset by interest expenses and bank fees on the
revolving  line  of  credit,  and  gains  or  losses  from  the  sale of assets.
Non-operating  income  in  3Q 1999 was $71, compared to $209 in 3Q 1998.  For 9M
1999, non-operating income was $293 compared to $836 in 9M 1998.  In both 1Q and
3Q 1998, UM enjoyed one-time payment from others' use of its pressure monitoring
technology.  Royalties  received  in  3Q 1999 were $18 less than in 3Q 1998, and
were  $98  less  in  9M  1999  than in 9M 1998.  Interest expenses and bank fees
associated  with  the  line  of credit were $93 in 3Q 1999 compared to $89 in 3Q
1998.  Royalties  received  vary  from  period to period depending on the desire
and/or  success  of  other companies in selling products licensed by UM, and the
remaining  life  of  UM's  patents.

     f)     Earnings  Before  Income  Taxes
          Earnings  before  income  taxes  (EBT)  result  from  adding  UM's
non-operating  income  to  its  operating profits.  Third quarter and first nine
months  1999  EBT, as a percentage of sales, were 30.7% and 28.8%, respectively,
compared  to 27.8% and 27.3% in 3Q and 9M 1998, respectively.  These profits are
comparable  to profits generated by well-performing companies with twice or more
the  sales  of UM.  EBT in 3Q and 9M 1999 were up 16.7% and 13.6%, respectively,
relative  to  the  same  periods  of  1998.

     g)     Net  Income  and  EPS
          Net  Income is EBT minus income taxes.  UM's Net Income expressed as a
percentage  of sales ranks in the top tier of all U.S. publicly-traded companies
at  18%  for 9M of both 1999 and 1998.  Net Income in 3Q 1999 increased 15% from
3Q  1998.  The  effective income tax rate in 3Q 1999 was 36.0% compared to 35.2%
in  3Q 1998.  The first nine months 1999 tax rate was 36.0% compared to 35.6% in
9M  1998.  Fluctuations  in  the  tax  rate result from  1) the use of a foreign
sales  corporation,  2)  differences  in  distribution of state income taxes, 3)
differences  in  profitability of the Ireland subsidiary which is taxed at a 10%
rate  on  manufactured  products,  4)  changes  in  the  amount of nondeductible
goodwill  expense resulting from a new acquisition, and 5) other factors such as
R&D  tax  credits  and  actual  litigation  costs  versus accrued expenses.  The
amortization  of  goodwill  associated  with  the  1997  Columbia  Medical, Inc.
acquisition  is  not  tax  deductible.
          Earnings  per  share  is Net Income divided by the number of shares of
stock  outstanding  (diluted to take effect for stock options awarded which have
exercise  prices  below  the current market value).  Diluted 3Q 1999 EPS were up
41%  compared  to  3Q  1998,  and 9M 1999 EPS increased 26% compared to the same
period  of 1998.  Third quarter 1999 weighted average diluted common shares (the
number  used to calculate diluted EPS) were down 19% compared to 3Q 1998.  First
nine  months 1999 diluted shares decreased 10% from 9M 1998.  Actual outstanding
common  shares  as  of September 30, 1999 (in thousands) were 6,453, compared to
8,229  shares  at  September  30, 1998.  In 3Q 1999, UM completed a tender offer
under  which  it  purchased  1.15  million  shares,  about  15%  of  shares then
outstanding.  Future  EPS  can  be  increased by investing current Net Income to
increase  future  net  profits through expanded product offerings and profitable
business  operations,  or  by repurchasing stock, thereby reducing the number of
outstanding  shares.  UM  believes  that  shareholder  value  is  improved  by
consistently  increasing  EPS.

     h)     Return  on  shareholders'  equity  (ROE).
          Return  on  Shareholders'  Equity  (ROE)  is the portion of net income
retained by UM  to internally finance its growth, divided by average accumulated
shareholders'  equity  during  the  period.  This  ratio determines how fast the
Company  can  afford to grow without external equity financing that would dilute
shareholder  interests.  For  example,  a  20%  ROE  will  support 20% growth in
revenues.  Achieving  growth  in  revenues  and EPS without diluting shareholder
interests  maximizes  shareholders'  value.  ROE in 3Q 1999 was 28%, compared to
20%  in  3Q  1998.
First  nine  months  1999  ROE  was  25%  compared  to  20%  in  9M  1998.

     i)     Cash  Flows
          EBITDA  (EBT,  adjusted  for  non-cash  depreciation  and amortization
expenses, asset dispositions, and interest expense and bank fees associated with
the  line of credit) is a measure of UM's ability to generate cash.  It may also
be  a better performance comparison measure when comparing to companies who have
made  acquisitions  using "Pooling of Interests."  First nine months 1999 EBITDA
were $8,095, compared to $7,749 in 9M 1998.  As a ratio of sales, EBITDA was 37%
in  9M  1999 and 38% in 9M 1998.  EBITDA has averaged 35% of sales over the last
five  years.  The  extraordinarily  strong  cash generation performance resulted
from  a  combination  of  excellent operating earnings, depreciation of existing
assets greatly exceeding replacement assets, and receipt of payments for the use
of  UM's  technology.  Because  of  EBITDA performance, UM was able to limit the
increase  in  its  long  term  debt  to  just  $5,440  despite paying $12,058 to
repurchase  more  than  1.6  million  shares  of  its  stock  in  9M  1999.
          Cash  (and  equivalent)  balances  were  $569 at the end of 9M 1999, a
reduction of $798 from December 31, 1998.  The decrease was primarily due to the
exercise and expiration of put contracts which required UM to set aside the full
purchase  price  of  the stock under contract, along with lower cash balances in
Ireland.  UM  effectively  maintains  zero-balance "sweep" cash account balances
that  minimize  the  line  of  credit  balance,  except for amounts held to meet
operating  requirements  in Ireland and separate physical reserves set aside for
litigation  expenses.
          Net  cash  provided by operating activities, including adjustments for
depreciation  and  other  non-cash  operating  expenses,  along  with changes in
working capital, was $524 lower in 9M 1999 than in 9M 1998.  Net working capital
changes  provided $723 to 9M 1999 cash, with the largest contributions (adjusted
for  exchange  rate  changes)  being  a $754 reduction in inventories and a $370
decrease  in  accrued interest and other receivables, offset partially by a $312
increase  in  trade  accounts  receivable.  Much larger decreases in inventories
during  9M  1998 explain the higher net cash provided by operating activities in
that  period  compared  to  9M  1999.
          Investing  activities  in  9M  1999  were comprised almost entirely in
improvements  to  property  and equipment.  Financing activities in 9M 1999 used
cash  of  $6,516,  including  $12,058  to purchase 1,606,000 shares of UM stock,
offset  by  an  increase of $5,444 in the line of credit.  UM received $98 in 9M
1999  compared  to  $58  in  9M 1999 from issuing stock (on exercise of employee
options).
          Planned  future  1999  capital  expenditures  will  keep  facilities,
equipment  and  tooling  in  good  working  order.  In  addition  to the capital
expenditures,  UM  plans  to  use cash for selective infusions of technological,
marketing  or  product  manufacturing  rights  to  broaden the Company's product
offerings,  for continued share repurchases while the price of the stock remains
extremely  undervalued,  and,  if available for a reasonable price, acquisitions
that  strategically  fit  UM's  business  and  are  accretive  to  performance.

     j)     Assets  and  Liabilities
          First  nine months-ending total assets were lower primarily because of
stock  repurchases, from reductions in inventories and other current assets, and
because  purchases  of  new  property  and  equipment  and intangibles were just
one-third  depreciation  and amortization amounts.  Inventory turns increased to
4.1  in  3Q  1999  from  2.7  in 3Q 1998 due to higher sales together with lower
inventory  levels.
          The  working  capital  decline of  $1,505 in 9M 1999 was primarily the
result  of  reductions  in  cash  and  inventories.  Through  its  excellent
profitability,  UM expects to internally finance any working capital growth that
is  needed  to  support  growth  in sales activity.  In 3Q 1999, UM's total debt
ratio  increased  to 39% of total assets from 19% at the end of 1998, due mainly
to  increases  in  the  line  of  credit.

     k)     Management's  Outlook
          UM  will continue to place emphasis on improving its U.S. direct sales
effectiveness.  An  experienced  National  Sales  Manager, hired in mid 1999, is
directing  an  extensive  initiative  to  track  communications  and commitments
throughout  the  sales cycle, and to see that every sales person understands the
clinical  value  of  every  UM  product.
          Access to U.S. hospital customers is increasingly constrained by group
purchasing  decisions.  To  be  successful  in  its  marketing programs, UM must
provide  clinicians  with  the information they need to make important judgments
about  using  certain  products  in  obtaining  optimal clinical outcomes, which
include  minimizing  risk  of  complications.  UM  must  also be able to provide
support for physicians to explain those needs to hospital administrators who are
primarily  focused  on  reducing  current  operating  costs.
          UM's  growing  number  of  gynecology  practice  tools are intended to
leverage  UM's activity with physicians outside the hospital.  The niche markets
for  which  UM's  gynecology/electrosurgery/urology  products  are targeted have
proven  to  require  many  and  varied  marketing  initiatives.  They  require
individual  user  training  together  with  clear evidence of improved outcomes.
UM's financial strength and stability allow it to patiently investigate economic
ways  to  increase  the  rate  of  adoption  of  its  newer  products.
          UM  will  continue  to  maintain  a  long-term perspective and seek to
strengthen  its  disease  management  focus  with physicians who it believes are
ultimately  responsible  for  their  patients'  well-being.

YEAR  2000
State  of  Readiness
--------------------
     UM  believes  it  will experience no material adverse consequences from the
"Year  2000  (Y2K) Problem," and is taking appropriate actions to see that it is
prepared  in  all of its operations globally.  UM has developed a Y2K plan it is
using  to  identify  and  solve  potential  Y2K  problems.
     The  Company  has  determined  that  all  of  the products it sells are Y2K
compliant  since  none  use  or  process  dates.
     An  inventory  of  all  known internal systems, along with testing of those
systems  has  been  completed.  Following  upgrade  or  replacement,  along with
subsequent testing of  systems initially identified as noncompliant, UM believes
its  internal  systems  are  Y2K  compliant.
     UM  has  surveyed  those  outside  vendors  it  considers  critical  to its
business,  including  utilities  and  other  providers  of  auxiliary  systems,
regarding  their  Y2K  readiness.  Response  assessment  and  implementation  of
appropriate  remedial  actions  are  expected  to  continue  throughout  1999.

Costs
-----
     UM  does  not  expect  its  Y2K  costs  to  be  material.  All  significant
replacements  or  upgrades  to  internal  systems  are  complete.  Total cost is
expected  to  be  less  than  (in  thousands)  $75.

Risks
-----
     As  UM's  products  do  not  incorporate date codes, Y2K risks based on its
products  are minor.  The risk of major internal systems failing is low based on
testing  and  vendor  assurances.  However,  although considered unlikely, it is
possible  that  a  major  Y2K  problem  might  be  identified.  UM has competent
employees  who  it  believes can find solutions to problems identified.  Perhaps
the greatest internal risk would be from a Y2K issue that remains hidden despite
diligent  testing.  If  such  a problem developed either shortly before or after
January  1,  2000,  UM could face delays and costs that might be material to its
business.
     UM  believes external Y2K problems constitute a higher magnitude of risk to
its  business.  If  mission critical vendors do not timely and accurately report
to  UM their Y2K readiness, or adequately solve Y2K problems as anticipated, the
Company's business could be materially impacted.  If alternate vendors cannot be
identified  and  qualified in time to replace vendors who are not Y2K compliant,
UM's  business  could  be  negatively  impacted.
     The  failure  of communications, financial and transportation systems could
have  a  major negative impact on UM, as would the failure of local utilities to
deliver  water,  natural  gas,  and  electricity.

Contingency  Plans
------------------
     Execution  of  the  Company's  Y2K  plan is UM's most important contingency
plan.  It  not  only  helps  identify  what  Y2K  risks UM faces, but provides a
framework  for how to solve them.  For example, UM is prepared to switch vendors
and  stock  excess  raw  material  and  finished goods inventory to mitigate Y2K
risks.  UM  employs skilled individuals who have the technical know-how to solve
most  challenges  likely  to  be  presented  by  the  Y2K  problem.
     UM believes that the most likely worst-case scenario would involve business
interruptions  of  up  to  one  or  two  weeks.  UM believes it could solve such
problems  before they became major risks to its business. UM does not believe it
can  develop  contingency  plans  to  deal  adequately  with  major  external
infrastructure failures such as in communications, transportation, or utilities.
However,  such  failures would likely not impact UM any more than it would other
businesses.

<PAGE>
                           PART II - OTHER INFORMATION

ITEM  6.  EXHIBITS  AND  REPORTS  ON  FORM  8-K

     a)     Exhibits:

               SEC
Exhibit  #     Reference  #        Title  of  Document
----------     ------------      -----------------------
   1               27            Financial  data  schedule


     b)    Reports  on  Form  8-K:
           During  the  quarter  ended  September 30, 1999, the Company filed no
           reports  on  Form  8-K.



                                   SIGNATURES

          Pursuant  to the requirements of the Securities Exchanges Act of 1934,
the  registrant  has  duly  caused this report to be signed on its behalf by the
undersigned  thereunto  duly  authorized.


                           UTAH MEDICAL PRODUCTS, INC.
                           ---------------------------
                              REGISTRANT





Date:    11/11/99       By:   /s/  Kevin  L.  Cornwell
      -------------         ------------------------------
                              Kevin  L.  Cornwell
                              CEO  and  CFO